Medindia

X

Key to Identifying, Enriching Mesenchymal Stem Cells Found

by Dr. Enozia Vakil on  June 22, 2014 at 5:56 PM Research News   - G J E 4
A biomarker that could help researchers characterize the properties and function of mesenchymal stem cells in the body has been found. MSCs are the focus of nearly 200 active clinical trials registered with the National Institutes of Health, targeting conditions such as bone fractures, cartilage injury, degenerative disc disease, and osteoarthritis.
 Key to Identifying, Enriching Mesenchymal Stem Cells Found
Key to Identifying, Enriching Mesenchymal Stem Cells Found
Advertisement

The finding, published in the journal Cell Stem Cell on June 19, significantly advances the field of MSC biology, and if the same biomarker identified in CRI's studies with mice works in humans, the outlook for clinical trials that use MSCs will be improved by the ability to better identify and characterize the relevant cells.

Advertisement
"There has been an increasing amount of clinical interest in MSCs, but advances have been slow because researchers to date have been unable to identify MSCs and study their normal physiological function in the body," said Dr. Sean Morrison, Director of the Children's Research Institute, Professor of Pediatrics at UT Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator. "We found that a protein known as leptin receptor can serve as a biomarker to accurately identify MSCs in adult bone marrow in vivo, and that those MSCs are the primary source of new bone formation and bone repair after injury."

In the course of their investigation, the CRI researchers found that leptin receptor-positive MSCs are also the main source of factors that promote the maintenance of blood-forming stem cells in the bone marrow.

"Unfortunately, many clinical trials that are testing potential therapies using MSCs have been hampered by the use of poorly characterized and impure collections of cultured cells," said Dr. Morrison, senior author of the study and holder of the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern. "If this finding is duplicated in our studies with human MSCs, then it will improve the characterization of MSCs that are used clinically and could increase the probability of success for well-designed clinical trials using MSCs."

Dr. Bo Zhou, a postdoctoral research fellow in Dr. Morrison's laboratory, was first author of the paper. Other CRI researchers involved in the study were Drs. Rui Yue and Malea Murphy, both postdoctoral research fellows. The research was supported by the National Heart, Lung, and Blood Institute, the Cancer Prevention and Research Institute of Texas, and donors to the Children's Medical Center Foundation.



Source: Newswise
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All